BeiGene
BGNE
#878
Rank
โ‚น1.918 T
Marketcap
โ‚น16,332
Share price
-5.56%
Change (1 day)
-1.40%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of June 2024 : โ‚น91.93 Billion

According to BeiGene 's latest financial reports the company's total debt is โ‚น91.93 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚น77.43 B56.83%
2022-12-31โ‚น49.37 B-4.5%
2021-12-31โ‚น51.70 B25.8%
2020-12-31โ‚น41.09 B107.8%
2019-12-31โ‚น19.77 B42.57%
2018-12-31โ‚น13.87 B31.9%
2017-12-31โ‚น10.51 B795.44%
2016-12-31โ‚น1.17 B-14.97%
2015-12-31โ‚น1.38 B57.5%
2014-12-31โ‚น0.87 B-48.12%
2013-12-31โ‚น1.69 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น22.72 B-75.28%๐Ÿ‡บ๐Ÿ‡ธ USA